AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From AScribe)
BOSTON -- Researchers at Dana-Farber Cancer Institute and a team of international collaborators have identified a genetic abnormality that makes some ovarian tumor cells initially sensitive to a common chemotherapy agent, cisplatin, and then resistant to the drug over time.
Published in the May issue of Nature Medicine, the study challenges conventional thinking about how cancer cells are able to "outsmart" therapies that at first are effective against them. "It has been thought that as normal cells evolve into cancerous ones, they acquire more and more genetic damage - to the point where they gain the ability to withstand drugs that once killed them," says the study's senior author, Alan D'Andrea, MD, of Dana-Farber and Children's Hospital Boston. "While that may indeed take place, our study points to another possibility: that cancer cells can, in…